Bayer Aktiengesellschaft (BAYRY) to Release Quarterly Earnings on Wednesday

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) is anticipated to issue its results before the market opens on Wednesday, March 4th. Analysts expect the company to announce earnings of $0.18 per share and revenue of $13.0754 billion for the quarter.

Bayer Aktiengesellschaft Trading Down 1.4%

BAYRY stock opened at $12.36 on Wednesday. Bayer Aktiengesellschaft has a 12 month low of $5.30 and a 12 month high of $14.85. The firm’s 50-day moving average is $12.26 and its 200 day moving average is $9.72. The company has a market capitalization of $48.57 billion, a PE ratio of -137.32, a P/E/G ratio of 4.96 and a beta of 0.68. The company has a debt-to-equity ratio of 1.10, a current ratio of 1.14 and a quick ratio of 0.71.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Barclays raised shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, January 6th. DZ Bank downgraded Bayer Aktiengesellschaft from a “strong-buy” rating to a “strong sell” rating in a report on Wednesday, February 18th. Zacks Research upgraded Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a report on Tuesday, January 20th. Morgan Stanley upgraded Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research note on Wednesday, December 3rd. Finally, JPMorgan Chase & Co. upgraded Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a report on Monday, December 8th. Three investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Bayer Aktiengesellschaft has a consensus rating of “Buy”.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.